ReviewPharmacology, biochemistry, and behavior2011
Alzheimer's disease and age-related memory decline (preclinical).
Review in Pharmacology, biochemistry, and behavior, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Huperzine A for mild cognitive impairment.The Cochrane database of systematic reviews · 2012Pooled it
- Exploring the neuroprotective, antioxidant, and anti-amyloid effects of Ganoderma lucidum compounds in Alzheimer's disease: insights from experimental and computational approaches.Journal, genetic engineering & biotechnology · 2026Article
- Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support.Food science & nutrition · 2025Review
- Exploring the molecular mechanisms of PPARγ agonists in modulating memory impairment in neurodegenerative disorders.Molecular biology reports · 2024Review
- Dissecting Alzheimer's Disease Risk in Asian American Elders: A Classification and Regression Tree Approach.Journal of Alzheimer's disease reports · 2024Article
- Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase.Metabolic brain disease · 2022Article
- An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.RSC medicinal chemistry · 2021Review
- Central administration of afzelin extracted from Ribes fasciculatum improves cognitive and memory function in a mouse model of dementia.Scientific reports · 2021Article
- Interaction of oxidative stress and neurotrauma in ALDH2Redox biology · 2020Article
- PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.Molecular neurobiology · 2019Review
- Neuroprotective Activity ofOpen access Macedonian journal of medical sciences · 2019Article
- Article
- Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease.Journal of enzyme inhibition and medicinal chemistry · 2018Article
- Electroacupuncture ameliorate learning and memory by improving N-acetylaspartate and glutamate metabolism in APP/PS1 mice.Biological research · 2018Article
- HO-1 dependent antioxidant effects of ethyl acetate fraction from Physalis alkekengi fruit ameliorates scopolamine-induced cognitive impairments.Cell stress & chaperones · 2018Article
- Ameliorative potential of desalted Salicornia europaea L. extract in multifaceted Alzheimer's-like scopolamine-induced amnesic mice model.Scientific reports · 2018Article
- Effects of chronic scopolamine treatment on cognitive impairment and neurofilament expression in the mouse hippocampus.Molecular medicine reports · 2018Article
- Nootropic and Neuroprotective Effects ofFrontiers in pharmacology · 2017Article
- Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice.Metabolic brain disease · 2016Article
- Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats.Journal of psychopharmacology (Oxford, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer's disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as "Mild Cognitive Impairment" (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD and MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy and adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.